A

Comprehensive

Laboratory

Manual

Featuring—

• Over 100 methods—
  just about every method used in a reference lab.

• Eleven chapters discussing problems faced by blood
  group serologists and the procedures and methods
  that can be used to solve them.

• An extra set of the methods to use at the bench,
  printed on durable waterproof paper.

• See business reply order card enclosed
  in this issue or order on the Web at
  redcross.org/immunohematology
APPLIED BLOOD GROUP SEROLOGY, 4th EDITION

by Peter D. Issitt and David J. Anstee

A totally revised, mostly rewritten, fully up-to-date edition of one of the most popular books about the blood groups and blood transfusion ever published.

- 46 chapters, an increase of 16 over the third edition
  - 1,208 plus xxiv 8½" × 11” pages, hardbound, fully indexed, over 1,500 entries
- 260 tables and 112 figures, an increase of more than 60% over the third edition
  - Over 13,500 references, more than 5,000 are papers written since 1985

Prices; each includes shipping: USA $125.00; Canada/International $130.00 (surface mail); International $170.00 (air mail).

ALL ORDERS MUST BE PREPAID
(Check or Credit Card) in U.S. DOLLARS

Order from:
Montgomery Scientific Publications, P.O. Box 2704, Durham, NC 27715, U.S.A.

Credit card orders accepted by fax at (919) 489-1235
(No phone orders, please.)

We accept VISA, MasterCard, and Discover Card.
CONTENTS

27
Practical aspects of investigating drug-induced immune hemolytic anemia due to cefotetan or ceftriaxone—a case study approach
P.A. Arndt

33
Neonatal alloimmune thrombocytopenia due to HPA-3a antibodies: a case report
A. Davoren, G. Smith, G. Lucas, S. Rodgers, P. O’Donoghue, J. Crowley, C.A. Barnes, and J. McKiernan

37
Anti-Mt<sup>e</sup> associated with three cases of hemolytic disease of the newborn

40
Moderate hemolytic disease of the newborn (HDN) due to anti-Rh17 produced by a black female with an e variant phenotype
M.C. Brumit, G.E. Carnahan, J.R. Stubbs, J.R. Story, and M.E. Reid

43
MIMA-9, a valuable antibody for screening for rare donors
E. Tossas, R. Øyen, G.R. Halverson, H. Malyska, and M.E. Reid

46
Confirmation that the JAHK antigen is associated with the r<sup>e</sup> haplotype
J. Kosanke, J.R. Story, and M.E. Reid

48
BOOK REVIEW
S. Gerald Sandler, MD

49
SPECIAL ANNOUNCEMENT

50
ANNOUNCEMENTS

51
CLASSIFIED ADS

51
ADVERTISEMENTS

53
LITERATURE REVIEW

58
INSTRUCTIONS FOR AUTHORS
Practical aspects of investigating drug-induced immune hemolytic anemia due to cefotetan or ceftriaxone—a case study approach

P.A. ARNDT

In the 1970s, the most common causes of drug-induced immune hemolytic anemia were methyldopa and penicillin. Since 1990, the most common causes of drug-induced immune hemolytic anemia have been the second- and third-generation cephalosporins, cefotetan and ceftriaxone. Three case histories illustrate the common findings in the serologic investigation of immune hemolytic anemias due to these two drugs. Immunohematology 2002;18:27–32.

Key Words: drug-induced immune hemolytic anemia, cefotetan, ceftriaxone, case studies

Presently, most drug-induced immune hemolytic anemias (IHAs) that our laboratory investigates are due to cefotetan, a second-generation cephalosporin, or ceftriaxone, a third-generation cephalosporin. The first case of ceftriaxone-induced IHA was referred to our laboratory in November 1987; since then we have identified nine more cases (40% of which were fatal). The first case of cefotetan-induced IHA was referred to our laboratory in March 1990; since then we have investigated 66 more cases (16% were fatal). In contrast, since November 1987, we’ve investigated only seven other cases of drug-induced IHA, one each due to cefotaxime, mefloquine, ticarcillin, or tolmetin, and three due to piperacillin.

The detailed serology of our first eight ceftriaxone and 43 cefotetan cases was published in 1999. The following three case studies are representative of the types of drug-induced IHA workups that we currently see in our laboratory. They illustrate some important points about investigating IHA due to cefotetan or ceftriaxone.

CASE 1

The patient was a 31-year-old woman who delivered her third child by cesarean section on March 4. She was discharged from the hospital on March 7 with a hemoglobin of 8.9 g/dL, but was readmitted on March 10 with hemolytic anemia (hemoglobin 8.7 g/dL, reticulocytes 10.5%, total bilirubin 3.5 mg/dL, LDH 503 U/L, haptoglobin < 6 mg/dL) and a 3+ positive direct antiglobulin test (DAT) with anti-IgG. Her serum contained anti-C and -e that had been previously identified and she had a history of a previous hemolytic anemia. On March 13 the hemoglobin decreased further to 6.1 g/dL and the patient was transfused with two units of red blood cells (RBCs).

The hospital blood bank technologists suspected that this patient had an antibody to cefotetan (Cefotan, Zeneca Pharmaceuticals, Wilmington, DE), as she had received two doses of that drug at the time of her surgery. These blood bank technologists had seen a previous patient with IHA due to cefotetan just 2 months earlier, so they were aware of these types of cases. The blood bank still had samples from the time of this patient’s surgery. The DAT was negative the day before surgery, before she received her first dose of cefotetan. It was 2+ the day after the surgery, after she had received her second dose.

The hospital technologists checked into the patient’s previous hemolytic anemia history and found that 3 years earlier, she had a cesarean section when delivering her second child and she received one dose of cefotetan at that time. Thirteen days after that surgery she was readmitted with hemolytic anemia (hemoglobin 5 g/dL, reticulocytes 15%, haptoglobin < 6 mg/dL) and she received four units of RBCs. In retrospect, the cause of this previous hemolytic anemia could also have been an antibody to cefotetan.

Further studies with this patient’s current sample showed the presence of IgG (4+), C3 (2+), and IgA (3+)
on her RBCs. We have found RBCs from patients with cefotetan-induced IHA to be coated with IgG 100 percent of the time, C3 86 percent of the time, IgA 44 percent of the time, and IgM 7 percent of the time.

Cefotetan-treated RBCs were prepared as previously described7–8: a 40 mg/mL solution of cefotetan in pH 7.3 phosphate buffered saline (PBS) was incubated with one-tenth volume of packed, fresh group O, C–e– RBCs for 1 hour at 37°C and then washed × 4. We would advise against using 6% albumin to prepare the cefotetan solution, as has been suggested for some other drugs, as cephalosporins bond efficiently to albumin. When testing drug-treated RBCs, controls are important. A positive control (i.e., a sample from a previous patient with the same drug antibody) will show that the treated RBCs are coated with the drug in question. Without this control, a negative result with the patient’s sample is difficult to interpret: is drug antibody not present or are the RBCs not coated with drug? A negative control is also important. For many drugs, a pool of normal “inert” serum can be used. But for some drugs, like cefotetan or cephalothin (Keflin), that cause nonimmunologic adsorption of serum proteins onto drug-coated RBCs9–12 the normal serum control will be reactive. This can be overcome when testing cephalothin-treated RBCs, by diluting the normal serum and the patient’s serum 1 in 20 (in PBS) to reduce the serum protein level before testing. Some normal sera diluted 1 in 20 are still reactive with cefotetan-treated RBCs (unpublished results), so a higher dilution of serum is recommended when testing cefotetan-treated RBCs (e.g., 1 in 100). Note: This low-titer reactivity of normal sera with cefotetan-treated RBCs has not been associated with hemolytic anemia, and in all cases of drug-induced IHA due to cefotetan that we have seen, the antibody titer has been greater than 100. Eluates can be tested without dilution as they have a low protein content. For drugs that are known to cause nonimmunologic protein adsorption, PBS can be used as a negative control.

The patient’s March 3 (presurgery, predrug) serum sample was shown to contain anti-cefotetan that reacted with cefotetan-treated RBCs to a titer of 512 by antiglobulin test (untreated RBCs tested in parallel were nonreactive). The presence of preformed anti-cefotetan in this sample thus confirmed that the hemolytic anemia seen 3 years previously was likely due to cefotetan. The patient’s March 10 (postdrug) serum sample reacted more strongly: the anti-cefotetan hemolyzed, agglutinated, and sensitized cefotetan-treated RBCs to titers of 128, 1024, and 128,000, respectively. The March 10 serum also reacted weakly with untreated RBCs by antiglobulin test. The presence of an autoantibody, i.e., drug-independent antibody, is not an uncommon finding in cases of IHA due to cefotetan. We found autoantibodies in about one-third of the patients with cefotetan-induced IHA that we studied (and up to 44%, if PEG was used in the test system).7

An acid eluate prepared from the patient’s RBCs reacted with cefotetan-treated RBCs both when anti-IgG (American Red Cross, Washington, DC) and when anti-IgA (Tago, Burlingame, CA) was used, indicating that the anti-cefotetan had both IgG and IgA components. Anti-IgA is not routinely used to test eluates, but was used in this case to determine if the IgA coating on the patient’s RBCs had anti-cefotetan specificity.

When eluates are tested against cefotetan-treated RBCs it is important to always test the last-wash supernatant control in parallel. Many times this last-wash control will react with cefotetan-treated RBCs (we found 74% to do so, 57% of these reacted ≥ 1+).7,13 Although this reactivity probably relates to the fact that serum cefotetan antibodies typically have very high titers (range 4000 to 262,000; median = 20,000), we found no direct relationship between the serum anti-cefotetan titer and the presence of a reactive last wash.12 There was a relationship seen between the presence of a reactive last wash and the strength of the patient’s DAT and/or the presence of autoantibody in the patient’s serum or eluate.13 Although increasing the number of times the patient’s RBCs are washed before eluate preparation is not always helpful, the type of wash solution that is used can be important. In general, we have found 4°C low-ionic-strength saline (LISS; Löw and Messeter formulation)14 to be better than PBS as a wash solution when performing acid eluates using commercial kits (we stopped using the commercial kit wash solution because of the problem of falsely positive eluates in the presence of high-titer serum antibodies).15 When LISS was used as a wash solution in cases of cefotetan-induced IHA, less strongly reactive last washes were seen.15 This may be because low-ionic solutions help keep more low-affinity antibodies on the RBCs during the washes.

Anti-cefotetan will also react when the patient’s serum is tested by the “immune complex” method.7 Briefly, 2 drops of the patient’s serum were incubated without or with 2 drops of fresh normal serum (as a source of complement) + 2 drops of a 1 mg/mL
solution of drug + 1 drop of C-e- untreated or enzyme-treated RBCs for 1 to 2 hours at 37°C. Tests were examined for hemolysis and agglutination and the antiglobulin test was performed. This patient’s March 10 serum reacted to a titer of 512 (antiglobulin test) versus untreated RBCs in the presence of cefotetan; enzyme-treated RBCs were strongly agglutinated; no hemolysis of test RBCs was observed.

In conclusion, this patient had a high-titer anti-cefotetan present in her serum, and her RBCs were also coated with anti-cefotetan. This antibody most likely caused the current hemolytic episode in addition to the hemolysis noted 3 years previously. This patient should be warned not to receive cefotetan again, as that may lead to a fatal hemolytic anemia.16

Some important points about cefotetan-induced IHA

- Cefotetan is a commonly used antibiotic, especially prophylactically with surgeries, e.g., cesarean sections.
- The hemolytic anemia usually becomes clinically apparent about 1 to 2 weeks after receiving cefotetan. Unfortunately, patients sometimes get more cefotetan at readmission (e.g., if an infection is suspected).
- A single dose of cefotetan can result in dramatic hemolytic anemia. In some cases, the hemolysis may take several weeks to subside.
- The DAT is positive; this can range from strongly (4+) to only weakly positive.
- Autoantibody (drug-independent antibody) may be present in the patient’s serum and/or eluate. Thus, this drug-induced IHA can be confused with warm autoimmune hemolytic anemia, or if the patient was transfused (e.g., during surgery when cefotetan was given), a delayed hemolytic transfusion reaction may initially be suspected.
- The serum antibody (anti-cefotetan) typically reacts to a very high titer with, and may completely hemolyze, cefotetan-treated RBCs.
- The serum antibody (anti-cefotetan) usually also reacts by the “immune complex” method, but more weakly.
- Eluates prepared from the patient’s DAT-positive RBCs will react strongly with cefotetan-treated RBCs.
- In a large percentage of cases, the last-wash eluate control will also react with cefotetan-treated RBCs, although usually weakly so. LISS appears to be a better wash solution than PBS for trying to reduce this problem.

CASE 2

The patient was a 76-year-old male who was admitted with a diagnosis of pneumonia. On day 1, his hemoglobin was 11.8 g/dL, creatinine 0.4 mg/dL, and serum and urine were clear. He was started on the antibiotic ceftriaxone (Rocephin; Hoffman-LaRoche, Nutley, NJ). On day 2, his creatinine was 1.0 mg/dL and hemoglobinemia was noted. On day 3, his hemoglobin/hematocrit were 8.8 g/dL/23%, total bilirubin was 1.5 mg/dL and hemoglobinuria, hemoglobinuria, and oliguria were noted. The ceftriaxone was stopped.

On day 4, his hematocrit was 21.2%, LDH 2858 U/L, serum hemoglobin 92.9 mg/dL, haptoglobin 16 mg/dL, and creatinine 4.3 mg/dL. He was transfused with two units of RBCs. Over the next 4 days, plasmapheresis was performed three times. The patient was discharged on day 11 with a creatinine of 8.9 mg/dL and no recovery of his renal function.

The patient’s DAT results were negative on day 1 (before drug administration) 2½+ with anti-C3 only on day 2, and then 1+ with anti-IgG and 3+ with anti-C3 on days 3 and 4. This patient’s hemolytic anemia was suspected to be due to anti-ceftriaxone. He had a history of multiple previous ceftriaxone treatments. Typically, patients with IHA due to ceftriaxone have received multiple doses of the drug.17 In some cases, patients have had previously unrecognized hemolytic episodes.

All of the ceftriaxone antibodies that we have worked with and those that have been reported have only reacted by the “immune complex” method (i.e., patient’s serum + drug + RBCs). When this patient’s sera were tested by the “immune complex” method, e.g., in the presence of ceftriaxone (1 mg/mL) against untreated RBCs, agglutination was noted (titers = 4 to 16); the antiglobulin test was negative to only very weakly positive. Controls of patient’s sera + PBS instead of drug were nonreactive, thus this patient’s serum contained anti-ceftriaxone.

In other cases, we have seen dramatic differences in reactivity when testing enzyme-treated RBCs by the “immune complex” method.7 For example, one patient’s anti-ceftriaxone reacted to titers of 4/0 (agglutination/antiglobulin test) against untreated RBCs but reacted to titers of 256/1024 against enzyme-treated RBCs. Unfortunately, titrations of the sera from case 2 against enzyme-treated RBCs were not performed. The agglutinin in case 2 was inhibited by treatment with 0.01M dithiothreitol (DTT), and therefore appeared to
be an IgM antibody. And, as in other cases of IHA due to ceftriaxone, the eluate was nonreactive.

Despite the fact that none of the previously identified ceftriaxone antibodies have reacted when tested against ceftriaxone-treated RBCs, if we have enough sample we sometimes attempt that method. We have tried coating RBCs with ceftriaxone dissolved in PBS (pH 7.3) or barbital buffer (pH 9.8), or by a chemical-coupling method, e.g., using carbodiimide. We tested this patient’s sera against RBCs that had been treated with ceftriaxone in PBS or barbital buffer. Sera from day 3 and day 4 agglutinated (2+ and 1+, respectively) not only drug-treated but also untreated RBCs; serum from day 5 was nonreactive. As the patient received his last dose of ceftriaxone on day 3, we believe that the positive results seen on days 3 and 4 were due to circulating drug-antibody immune complexes that were still present in the samples from those days (the half-life of ceftriaxone is about 9 hours in elderly subjects, and about 15 hours in patients with impaired renal function). These immune complexes had cleared by day 5. If autoantibody had been present it would have still been detectable in the day 5 sample. If the anti-ceftriaxone had indeed been reacting with these ceftriaxone-treated RBCs, it should also have been detected in the day 5 sample. Note: Since no anti-ceftriaxone has ever been shown to react with ceftriaxone-treated RBCs, we had no positive control to prove that these treated RBCs were indeed coated with ceftriaxone.

In conclusion, this patient developed an anti-ceftriaxone that caused intravascular hemolysis and renal failure.

Some important points about ceftriaxone-induced IHA

- The patients have typically received multiple doses of ceftriaxone previously.
- In adults, the reaction tends to become apparent after the patient has received the drug for a day or two. In children, the reactions tend to be very dramatic, occurring within minutes of receiving ceftriaxone.
- The DAT is positive due to C3 or C3 + IgG coating. The eluate is usually nonreactive.
- Ceftriaxone antibodies have only been demonstrated by the “immune complex” method (enzyme-treated RBCs react better than untreated RBCs); drug-treated RBCs are nonreactive. In two cases, antibody was only demonstrable in the presence of ex vivo drug (urine from patients receiving ceftriaxone).
- Reactivity of the patient’s serum against untreated RBCs without drug being present can be due to circulating drug-antibody immune complexes (if transient) or due to autoantibody (if persistent). This is true of any drug, not just ceftriaxone.

CASE 3

We received a telephone call from a pathologist at a commercial reference laboratory about a ceftriaxone antibody workup on a postsurgical patient who had a positive DAT and a hemoglobin of 5 g/dL.

The sample arrived a few days later with more information. The patient, a 59-year-old woman, had surgery a couple of weeks earlier and then developed a postoperative infection. On December 20, her hemoglobin was 10.3 g/dL and she received 1 g of ceftriaxone. On December 21, her hemoglobin had decreased to 8.2 g/dL and she received another 1 g of ceftriaxone. On December 22, her hemoglobin had decreased further to 5 g/dL and the ceftriaxone was discontinued. Her DAT was positive, her reticulocyte count was 3.7%, and she was transfused with four units of RBCs.

When the hospital blood bank was called to verify the patient’s identification (she had the same name as another patient we had previously worked up with an IHA due to anti-cefotetan), we were told that the doctor remembered that this patient had received ceftriaxone with her bowel surgery a few weeks earlier. Thus, this patient’s history was what we might expect with a ceftriaxone antibody, i.e., the patient had received the drug before and the reaction had taken a day or two to become apparent (as seen in adults).

The patient’s DAT was positive (anti-IgG 1+, anti-C3 3+), but the “immune complex” testing in the presence of ceftriaxone was negative! Thus, this patient did not have a ceftriaxone antibody. We wondered, what if we had been given an incorrect history? What if the patient had received another drug (e.g., cefotetan) during the surgery a few weeks previously and not ceftriaxone? The time frame of hemolysis a couple of weeks after surgery is what would be expected in a case of cefotetan-induced IHA.

The patient’s serum and eluate were tested against cefotetan-treated RBCs and found to contain anti-cefotetan. The undiluted serum hemolyzed cefotetan-treated RBCs and when diluted reacted to titers of 320 and 10,240 (agglutination and antiglobulin test,
respectively). Untreated RBCs were nonreactive. The hospital blood bank was contacted and asked to determine if the patient had received cefotetan during the surgery. They checked the records and discovered that the patient had received 2 g of cefotetan with her surgery on December 10; she had been readmitted on December 20, exactly 10 days later. Luckily, she did not receive more cefotetan at the time of readmission.

In conclusion, this patient had an IHA due to anti-cefotetan, not anti-ceftriaxone.

An important point illustrated by this case

• A good history is important and may be difficult to obtain. When a drug-induced IHA is suspected, it is important to find out not only what drug(s) the patient is currently taking, but also what the patient received (e.g., in surgery) a few weeks back. This information often is “hidden” in the anesthesiologist’s notes and can take some detective work to discover.

Acknowledgments

The author would like to acknowledge the many contributions of Dr. George Garratty and Regina Leger to the contents of this report. Their helpful comments on the manuscript were also appreciated.

References


Patricia A. Arndt, MS, MT(ASCP)SBB, Senior Research Associate, Immunohematology Research Laboratory, American Red Cross Blood Services, Southern California Region, 1130 South Vermont Avenue, Los Angeles, CA 90006. e-mail: arndtp@usa.redcross.org

Manuscripts: The editorial staff of Immunohematology welcomes manuscripts pertaining to blood group serology and education for consideration for publication. We are especially interested in case reports, papers on platelet and white cell serology, scientific articles covering original investigations, and papers on the use of computers in the blood bank. Deadlines for receipt of manuscripts for the March, June, September, and December issues are the first weeks in November, February, May, and August, respectively. Instructions for scientific articles and case reports can be obtained by phoning or faxing a request to Mary H. McGinniss, Managing Editor, Immunohematology, at (301) 299-7443, or see “Instructions for Authors” in every issue of Immunohematology or on the Web. Include fax and phone numbers and e-mail address with your manuscript.

IMPORTANT NOTICE ABOUT MANUSCRIPTS FOR IMMUNOHEMATOLOGY
Submit all manuscripts (original and 2 copies) to Mary H. McGinniss, Managing Editor, 10262 Arizona Circle, Bethesda, MD 20817. Please include the manuscript on a 3 1/2 inch disk, in Microsoft Word 97/6.0 or WordPerfect 6.0/5.1, and e-mail a copy to mmanigly@usa.redcross.org
Neonatal alloimmune thrombocytopenia due to HPA-3a antibodies: a case report

A. Davoren, G. Smith, G. Lucas, S. Rodgers, P. O’Donoghue, J. Crowley, C. A. Barnes, and J. McKiernan

A healthy infant was born at term by elective cesarean section to a 32-year-old para 4, gravida 4, mother. Within 24 hours, the infant was noted to have fairly extensive bruising on the back and shoulders. A full blood count evaluation was remarkable for severe thrombocytopenia (platelet count of $29 \times 10^9/L$). Other hematologic parameters were normal. Human leukocyte antigen (HLA) class-1 antibodies but not platelet-specific antibodies were detectable in the maternal serum using a commercial antigen-capture ELISA (GTI-PakPlus kit®). Anti-HPA-3a antibodies, while weakly reactive in the monoclonal antibody immobilization of platelet antigens (MAIPA) assay in the immediate postpartum serum, were readily detectable using this assay in a sample taken 4 weeks later. Genotyping for human platelet antigens (HPA) 1–5 by the polymerase chain reaction technique with sequence-specific primers (PCR-SSP) revealed the infant’s platelet genotype to be $\text{HPA-1a/1a, 3a/3b,}$ while that of the mother was $\text{HPA-1a/1a, 3b/3b,}$ consistent with a diagnosis of anti-HPA-3a neonatal alloimmune thrombocytopenia (NAIT). This case illustrates the increased sensitivity of the MAIPA technique for the detection of platelet-specific antibodies. We believe this to be the first serologically confirmed case of NAIT due to anti-HPA-3a to be reported in the republic of Ireland. Immunohematology 2002;18:33–36.

Key Words: anti-HPA-3a, MAIPA, NAIT

Neonatal alloimmune thrombocytopenia (NAIT) is the result of platelet destruction by maternal IgG alloantibodies directed against antigens on fetal/neonatal platelets.1 It occurs in approximately 1 in 1000 live births.2,3 Clinical sequelae vary from asymptomatic thrombocytopenia in some infants to intracranial hemorrhage in the more severely affected cases.3,4 There is a reported mortality in NAIT of up to 10 percent of affected infants, while a further 10–20 percent suffer varying degrees of neurologic impairment due to intracranial hemorrhage.3,4 Several human platelet antigen (HPA) systems have been identified.8 Most are biallelic, with the high-frequency antigen being designated the “a” antigen and the low-frequency antigen, the “b” antigen. HPA-1a is the most clinically relevant platelet antigen in Caucasians, with anti-HPA-1a alloimmunization in $\text{HPA-1b}$ homozygous mothers accounting for approximately 85 percent of cases of NAIT.4 An additional 10–15 percent of cases are caused by HPA-5b antibodies.4 NAIT due to other platelet antigen incompatibilities is relatively uncommon. We describe a case of NAIT due to maternal HPA-3a alloimmunization.

Case Report

A 32-year-old mother gave birth to her fourth child by elective cesarean section after an uncomplicated pregnancy. She had three previous healthy children and an uncomplicated obstetric and perinatal history. She had not taken any medications during her current pregnancy, had no history of blood transfusion, was immune to rubella, and was negative for hepatitis B surface antigen.

The male infant (birth weight: 3820 g) was generally healthy at birth, with Apgar scores of 9 and 10 at 1 and 5 minutes, respectively. Approximately 24 hours after delivery, the infant was noted to be irritable and physical examination revealed the presence of petechiae and bruising on the left arm and back, extending to the right shoulder region. The infant’s platelet count was $29 \times 10^9/L$, hemoglobin 16.4 g/dL, activated partial thromboplastin time (APTT) 34 seconds (control 26 to 32 seconds), and international normalized ratio (INR) 1.3. Red and white blood cell counts were normal. There was no evidence of infection, malformation, hemangioma or hepatosplenomegaly. The maternal platelet count was normal and there was no familial history of bleeding disorders or NAIT. Blood cultures were negative. A clinical diagnosis of NAIT was made and the infant was observed closely in the special care baby unit, where he remained well with no extension of bruising, and his behavior was normal. Platelet transfusion was not required. At discharge on day 7, the infant’s platelet count was $118 \times 10^9/L$. At follow-up 4 weeks after discharge from the
hospital, the baby was developing normally and had a normal platelet count (353 × 10^9/L).

Materials and Methods

A maternal serum sample, obtained after delivery, was tested for platelet-reactive antibodies, using a commercial antigen-capture enzyme-linked immunosorbent assay (ELISA) kit (GTI-PakPlus® ELISA, Quest Biomedical, Knowle, West Midlands, UK). This kit was used with an IgG conjugate and in accordance with the manufacturer’s instructions. The mother’s serum was also referred to the International Blood Group Reference Laboratory (IBGRL), Bristol, UK, for testing by the platelet suspension immunofluorescence technique (PSIFT) and by the monoclonal antibody immobilization of platelet antigens (MAIPA) assay. The immunofluorescence test was assessed by the use of flow cytometry. A maternal serum sample obtained 4 weeks later for repeat investigation was referred to both the IBGRL and the Platelet Immunology Reference Laboratory, National Blood Service, Cambridge, UK. HPA genotyping was performed using the polymerase chain reaction technique with sequence-specific primers (PCR-SSP) for HPA 1–5.

Results

Human leukocyte antigen (HLA) antibodies class-I, but not platelet-specific antibodies, were detectable in both the serum sample obtained after delivery and the repeat sample taken 4 weeks later, using the GTI PakPlus® kit. The patient’s serum bound both IgG and IgM to the surface of platelets in the immuno-fluorescence test. While weakly reactive HPA-3a antibodies were identified by the MAIPA assay in the immediate postpartum serum, in addition to HLA class-I antibodies, anti-HPA-3a was readily detectable in a sample taken 4 weeks later.

The mother’s platelet genotype was HPA-1a/1a, HPA-3b/3b, and the infant typed as HPA-1a/1a, HPA-3a/3b, as determined by PCR-SSP. These results were consistent with a diagnosis of NAIT due to maternal HPA-3a antibodies. Paternal platelets were unavailable for typing or crossmatch studies with maternal serum.

Discussion

NAIT occurs in approximately 1 in 1000 pregnancies. HPA-1a antibodies account for about 85 percent of cases and anti-HPA-5b for 10–15 percent of cases. NAIT resulting from alloimmunization to the HPA-3a (Bakc) antigen in HPA-3b homozygous mothers is rare (< 1% of documented cases).

Of 27 cases of serologically confirmed NAIT diagnosed in Ireland between January 1992 and December 2000 (A. Davoren, in press), 25 (93%) were due to HPA-1a antibodies, one was due to HPA-5b antibodies, and one (this case) was due to HPA-3a antibodies. In the study by Mueller-Eckhardt, et al., only one out of 121 serologically confirmed cases of NAIT was due to HPA-3a antibodies.

Antibodies to the HPA-3a (Bakc) antigen system were originally described in 1980 and the antigen was localized to glycoprotein IIa. In that first reported case, the first child of a healthy mother developed severe thrombocytopenia and died of a cerebral hemorrhage on day 4 of life. Only a small number of cases have been reported since 1980 but all have been associated with severe thrombocytopenia (platelet count < 30 × 10^9/L). One infant sustained an intracranial hemorrhage with residual hemiparesis, mental retardation, and epilepsy. Thus, although HPA-3a would appear to be significantly less immunogenic than either HPA-1a or -5b, NAIT caused by HPA-3a antibodies is similar in its severity to anti-HPA-1a-induced disease. Furthermore, the duration of thrombocytopenia associated with HPA-3a alloimmunization may be prolonged.

Improvements in platelet antibody detection techniques and PCR technology have led to increased diagnosis of NAIT in recent years. However, considerable inconsistency in test results between laboratories continues to be reported for antibodies other than anti-HPA-1a. The fragility of the Bakc epitopes has been demonstrated previously and may account for the difficulties sometimes encountered in the detection of these antibodies.

The use of a commercial antigen-capture ELISA (GTI PakPlus®) failed to detect the HPA-3a antibody in this case. In contrast, the MAIPA assay was able to detect HPA-3a antibodies in both the immediate postpartum serum sample (weakly) and, more readily, in the sample taken 4 weeks later.

The advantages of the MAIPA assay for HPA alloantibody detection compared to the GTI kit have been previously documented. In the MAIPA technique, monoclonal antibodies are used to isolate the various platelet glycoproteins from each other, thus permitting analysis of mixtures of antibodies directed against different antigens.

This case highlights potential difficulties that may be encountered in the detection of platelet-specific
antibodies and illustrates that more than one assay, combined with platelet genotyping, may be required for the diagnosis of NAIT. Weak or undetectable antibodies can be boosted to readily detectable levels in the weeks after delivery. Thus, it is important to obtain follow-up samples from patients where there is a strong clinical suspicion of NAIT. Accurate characterization of the responsible platelet-specific antibody is important to enable appropriate counseling of the parents regarding future pregnancies and to avoid complications if blood transfusions are required.

References
Phone, Fax, and Internet Information: If you have any questions concerning Immunohematology, Journal of Blood Group Serology and Education, or the Immunohematology Methods and Procedures manual, contact us by e-mail at immuno@usa.redcross.org. For information concerning the National Reference Laboratory for Blood Group Serology, including the American Rare Donor Program, please contact Sandra Nance by phone at (215) 451-4362, by fax at (215) 451-2538, or by e-mail at snance@usa.redcross.org.

Free Classified Ads and Announcements: Immunohematology will publish classified ads and announcements (SBB schools, meetings, symposia, etc.) without charge. Deadlines for receipt of these items are as follows:

**Deadlines**

- 1st week in January for the March issue
- 1st week in April for the June issue
- 1st week in July for the September issue
- 1st week in October for the December issue

Fax these items to Mary H. McGinniss, Managing Editor (301) 299-7443.
Anti-Mt\textsuperscript{a} associated with three cases of hemolytic disease of the newborn


The Mt\textsuperscript{a} antigen is a low-frequency red blood cell (RBC) surface antigen and is an established antigen of the MNSs blood group system. There has been one report of anti-Mt\textsuperscript{a}-induced hemolytic disease of the newborn (HDN) in the literature to date. We describe a family in which three children were affected by neonatal anemia. The clinical and hematologic findings were consistent with HDN, despite repeatedly negative direct antiglobulin tests (DAT) on cord RBCs. Serologic investigations showed that the mother's serum contained anti-Mt\textsuperscript{a}. The father and all three children phenotyped as Mt\textsuperscript{a+}, while the mother was Mt\textsuperscript{a−}. Adsorption and elution experiments gave results which suggested that anti-Mt\textsuperscript{a} may be implicated in recurrent HDN in this family.

**Key Words:** Mt\textsuperscript{a}, MNSs blood group system, hemolytic disease of the newborn (HDN), direct antiglobulin test (DAT)

The rare Mt\textsuperscript{a} antigen was first described by Swanson and Matson in 1962.\textsuperscript{1} In a kindred with four generations available for testing, they demonstrated that Mt\textsuperscript{a} was a red blood cell (RBC) antigen of the MNSs system, and the inheritance pattern was autosomal dominant. Subsequently, work by Konugres et al.\textsuperscript{2} produced anti-Mt\textsuperscript{a} in rabbits. This allowed large-scale screening to be performed. Twenty-nine Mt\textsuperscript{a+} individuals were detected among 12,914 unrelated people in Boston, and all 29 were also N+s+\textsuperscript{2}.

There is only one report published of Mt\textsuperscript{a}-associated pathology. Field et al.,\textsuperscript{3} in 1972, described a family in which the third child was affected by hemolytic disease of the newborn (HDN).\textsuperscript{3} The father, the second child, and the newborn were all Mt\textsuperscript{a+}, while the mother was Mt\textsuperscript{a−}. Anti-Mt\textsuperscript{a} was eluted from the newborn’s RBCs.

In the following report, we describe a family in which all three live children were affected by HDN to varying degrees. Anti-Mt\textsuperscript{a} was identified in the maternal serum, while the father and all three children were Mt\textsuperscript{a+}. Extensive investigations for causes of hemolytic anemia in the children did not establish alternative diagnoses. Circumstantial evidence, therefore, suggests that anti-Mt\textsuperscript{a} caused HDN in all three cases.

**Materials and Methods**

**Sample collection**

Whole blood was collected in EDTA, then centrifuged at 3000 rpm for 10 minutes to separate RBCs from plasma, then stored at 4°C until used.

**Routine antibody screen**

The Ortho Biovue\textsuperscript{TM} System (Ortho-Clinical Diagnostics, Raritan, NJ) was used for routine antibody screens. The Ortho Biovue System uses cassettes containing six columns of glass beads. Each column contains anti-IgG and -C3d polyspecific anti-human globulin (rabbit and murine monoclonal) in solution. Screening by the indirect antiglobulin test (IAT) uses group O reagent RBCs supplied by CSL Ltd., Parkville VIC, Australia. Ten \( \mu \text{L} \) of a RBC suspension (3% to 5%) and 40 \( \mu \text{L} \) of patient’s plasma are added to a reaction chamber above a column. The cassette is incubated at 37°C for 10 minutes (Ortho Biovue\textsuperscript{TM} System heat block), then centrifuged in an Ortho Biovue\textsuperscript{TM} System centrifuge. RBCs retained in or above the glass bead column is a positive result. Samples giving a positive result were tested further. A button of packed RBCs at the bottom of the column represents a negative result.

**Direct antiglobulin test (DAT)**

Approximately 200 \( \mu \text{L} \) of packed RBCs are washed \( \times 3 \) in buffered normal saline (0.9%). Two drops of anti-human globulin (anti-IgG and -C3d, CSL, Ltd.) are added to the cell button. The sample is centrifuged at 3000 rpm for 15 seconds and examined both macroscopically and microscopically. If the test is negative, it is left at room temperature for 5 minutes, then recentrifuged and examined. One drop of IgG-sensitized RBCs is added to negative tests as a control for the anti-human globulin reagent.

**Eluates**

Elution was performed using the heat method and eluates were tested by BioVue\textsuperscript{R} IAT.
**PEG indirect antiglobulin test**

Polyethylene glycol (PEG)-IAT was carried out with PeG™, supplied by Gamma Biologicals, Inc., Houston, Texas, in accordance with the manufacturer's directions.

**Case History**

The mother was a healthy 38-year-old woman in her fifth pregnancy by the same partner. Her blood group was A, D+ with no antibody detected on routine screening using the BioVue®(Ortho) system. Her husband was also A, D+. She had two miscarriages before her first liveborn group A, D+ child, now 10 years old. This child was born at term with severe anemia, gross hepatosplenomegaly, and hydrops, but direct antiglobulin test (DAT) negative. At birth the hemoglobin was 48 g/L, accompanied by marked polychromasia on blood film, and she required packed RBC transfusions and intensive care support. Recovery was prompt and her hemoglobin eventually increased to normal. Investigations for intrauterine infection and other possible causes of anemia yielded no definite diagnosis. There were no long-term sequelae, and subsequent development was normal.

The second child was born 3 years later. He was delivered by cesarean section at 39 weeks of gestation due to fetal distress. He was jaundiced at birth, with a low hemoglobin for his age (110 g/L) and elevated serum bilirubin level of 107 µmol/L (reference range 0–15 µmol/L). His blood group was A, D+, and the DAT was negative. He was treated with phototherapy. Exchange transfusion was not required. About 2 weeks postdelivery, he was readmitted with a hemoglobin level of 72 g/L. No hepatosplenomegaly was evident. Extensive investigations were carried out to exclude hereditary conditions such as a hemoglobinopathy, RBC enzyme, or membrane defect. No definite diagnosis was established. He recovered spontaneously without transfusion and with subsequent normalization of his hemoglobin on follow-up. His subsequent development was also normal.

The proband was the third child, born in February 2000. He had been monitored antenatally as a high-risk pregnancy, and he was delivered by cesarean section at 34 weeks of gestation for moderate polyhydramnios and mild hydrops. At birth he was in respiratory distress, pale, and jaundiced. There was moderate hepatosplenomegaly. His hemoglobin level was 108 g/L, his blood group was A, D+, and the DAT was negative. His serum bilirubin at birth was 90 µmol/L and it peaked at 162 µmol/L on day 3. A RBC exchange transfusion and intensive care support were instituted. He responded well to treatment, requiring only one exchange transfusion, and was discharged after 2 weeks. His hemoglobin on follow-up has been normal.

The newborn's blood film showed marked polychromasia and erythroblastosis. The appearance was consistent with moderate to severe hemolysis associated with HDN. Further serologic investigations were pursued in spite of the negative DAT result on his RBCs.

The mother's serum was tested against the father's RBCs. The test was positive by IAT using the BioVue®(Ortho) system. This was further evidence for maternal RBC antibody as the cause of the clinical picture. Since the mother had no detectable antibody in her plasma on routine screening with commercial screening cells, this finding suggested an antibody to a low-frequency antigen. The case was referred to an Australian Red Cross reference laboratory.

At the reference laboratory, antibody screening of the mother's serum was repeated with commercial screening cells, using room temperature saline, papain-treated indirect antiglobulin test (papain-IAT), and polyethylene glycol indirect antiglobulin test (PEG-IAT). Again, no antibody was detected.

Further testing involved crossmatching the mother's serum with her husband's RBCs and the baby's RBCs. Both the husband's RBCs and the baby's RBCs were strongly incompatible with the mother's serum, but this was demonstrable only by the PEG-IAT method. Because they reacted in an identical pattern, this suggested that both baby and husband expressed the same low-frequency antigen. Absence of reaction by the papain method suggested the antigen was sensitive to papain. DTT-treated serum resulted in no reduction in reaction strength, indicating the antibody was not IgM and, therefore, likely to be IgG.

Based on the above tests, a literature search was performed to identify candidate low-frequency antigens. The MNS system was the first to be closely examined, as it is known that most antigens in this system are enzyme sensitive, and there are a number of low-frequency antigens whose alloantibodies have been associated with HDN. Further testing of the mother's serum against a panel of low-frequency antigens was performed. Strong reactions were detected against four Mta+ RBCs by PEG-IAT.

Phenotyping of RBCs from the father and the three children with anti-Mta demonstrated that they were all Mta+, while the mother was Mta–. Although an eluate prepared from the neonate's cord RBCs did not show Mta activity, anti-Mta was weakly detectable in the serum.
from the cord blood sample. ABO, Rh, and MNSs phenotypes of the father, mother, and the three children are shown in Table 1.

Table 1. Family phenotype

<table>
<thead>
<tr>
<th>Family</th>
<th>ABO, Rh</th>
<th>Rhesus*</th>
<th>MNSs</th>
<th>MT*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mother</td>
<td>A, D+</td>
<td>CD/cDE</td>
<td>M+N+S++</td>
<td>Mtα-</td>
</tr>
<tr>
<td>Father</td>
<td>A, D+</td>
<td>cDE/cDE</td>
<td>M+N+S++</td>
<td>Mtα+</td>
</tr>
<tr>
<td>1st child</td>
<td>A, D+</td>
<td>cDE/cDE</td>
<td>M-N+S-</td>
<td>Mtα+</td>
</tr>
<tr>
<td>2nd child</td>
<td>A, D+</td>
<td>CDe/cDE</td>
<td>M-N+S-</td>
<td>Mtα+</td>
</tr>
<tr>
<td>3rd child</td>
<td>A, D+</td>
<td>cDE/cde</td>
<td>M-N+S-</td>
<td>Mtα+</td>
</tr>
</tbody>
</table>

*Most probable Rh phenotype

Adsorption of the mother’s serum by RBCs from her second child resulted in a positive DAT. The antibody was shown to be IgG, based on the specific antiglobulin reagent. An eluate from these cells reacted against known Mtα+ RBCs, thereby confirming the specificity of the antibody.

Discussion

In this family, three children were born with variable degrees of anemia, jaundice, and hydrops. All of them recovered after the perinatal period, maintaining normal hemoglobin levels on follow-up. The most common cause of such a clinical scenario would be HDN. Intrauterine infections were excluded after all three births. Hereditary RBC or hemoglobin defects would be unlikely given the negative investigation results at presentation, as well as subsequent normal hemoglobin levels in all three children. Given (1) that the mother’s serum contained anti-Mtα, (2) that the father and all three children are Mtα+, and (3) the exclusion of other common causes for such a clinical presentation, the finding of anti-Mtα is considered to be the likely cause of recurrent HDN in this family.

Under the circumstances, it was not possible to prove definitively that anti-Mtα was the cause of HDN. Proof would have required that the neonate’s RBCs be demonstrably coated with antibodies (i.e., DAT positive) and that the eluate from the neonate’s cells be reactive against known Mtα+ RBCs. In this baby’s case, as was the case with his older brother, the DAT had been consistently negative, and elution was attempted but did not demonstrate anti-Mtα.

In the current case, the sensitizing events for the mother could have been the two miscarriages before her liveborn children.

One confusing factor in the management of this case was the repeatedly negative DATs on cord cells of the affected children. In contrast, in the case described by Field et al.,3 a strongly positive DAT was demonstrated on the baby’s RBCs. This variation in clinical presentation remains unexplained, but it serves to illustrate that a negative DAT on anemic neonates may not necessarily exclude HDN.

References


Carol C. Cheung (corresponding author), MBBS, Haematology Registrar, South Eastern Area Laboratory Services—Transfusion Services, Prince of Wales Hospital, Sydney, NSW 2031, Australia; Daniel Challis, FRANZCOG, Staff Specialist in Maternal Fetal Medicine, Dept. of Maternal Fetal Medicine, Royal Women’s Hospital, Sydney, Australia; George Fisher, BSc, Senior Scientist, South Eastern Area Laboratory Services—Transfusion Services, Prince of Wales Hospital, Sydney, Australia; Susan J. Russell, FRACP, Staff Specialist, Dept. of Hematology/Oncology, Sydney Children’s Hospital, Randwick; School of Paediatrics, University of New South Wales, Sydney, Australia; Andrew Davis, BSc Grad Dip IM, Scientist, NSW State Red Cell Reference Laboratory, Australian Red Cross Blood Service, Sydney, Australia; Hayley Bruce, BSc Hons, Scientist, NSW State Red Cell Reference Laboratory, Australian Red Cross Blood Service, Sydney, Australia; Julie Watt, BSc, Senior Scientist, Officer-in-charge, NSW State Red Cell Reference Laboratory, Australian Red Cross Blood Service, Sydney, Australia; Beng H. Chong, PhD, FRACP, FRCPA, Professor and Head, Department of Medicine, St George Hospital Clinical School, University of NSW, Level 2, WR Pitney Building, St George Hospital, Belgrave Street, Kogarah, Australia.
Moderate hemolytic disease of the newborn (HDN) due to anti-Rh17 produced by a black female with an e variant phenotype

M.C. BRUMIT, G.E. CARNAHAN, J.R. STUBBS, J.R. STORRY, AND M.E. REID

The Rh blood group antigen e is of high incidence and has many epitopes. Partial expression may occur, more commonly in black persons. Individuals with e variant phenotypes can make antibodies to epitopes they lack. While some of these antibodies may be specific for an antigen, e.g., hr6, others, like anti-Rh17 (anti-Hr0), show broader specificity, compatible only with D– – and Rhnull red blood cells (RBCs). Anti-Rh17 in persons of the D– – phenotype has been reported to cause mild to fatal HDN. We report an example of anti-Rh17 produced by a black female with an e variant RBC phenotype that caused moderate HDN. A panel of seven monoclonal anti-e demonstrated her RBCs carried a variant e antigen, and her genotype was RHD, RHce by PCR-RFLP analysis.

Amniotic fluid with ΔOD450 values from 30 to 35 weeks' gestation predicted moderate HDN probability by the Liley method. At 38+ weeks, a viable 3165 g female infant was delivered. The infant's direct antiglobulin test was 2+ with anti-IgG. Total bilirubin rose to 14.2 mg/dL within 48 hours. Indirect bilirubin peaked at 14.7 mg/dL. The bilirubin responded to triple phototherapy. The infant was discharged on day 6. Potential for infant morbidity due to anti-Rh17-mediated HDN and the importance of specifying risks to women with this antibody if they contemplate pregnancy are discussed. Immunohematology 2002:18:40–42.

Key Words: hemolytic disease of the newborn (HDN), anti-Rh17, variant e phenotype

The Rh blood group antigen e occurs with an incidence of approximately 98 percent and consists of many epitopes.1 Partial expression, and thus the absence of specific epitopes, can occur particularly in black persons. After transfusion or, less often, pregnancy, individuals with partial e expression can become immunized to the various epitopes of the RhCE protein that they lack.2 Anti-Rh17 usually occurs in individuals with various deletion phenotypes such as D– –, and has been reported as a cause of mild to fatal hemolytic disease of the newborn (HDN). Pregnanacies as early as the second and late as the fifth have been affected. In addition to HDN, previously reported cases describe loss of pregnancy and maternal hemorrhage. Such complications occurred in first as well as higher order gestations.3-5 Anti-Rh17 also occurs in individuals with variant expression of the e antigen and is sometimes noted as anti-Rh17-like. We report moderate HDN due to anti-Rh17 during the second pregnancy in a woman with e variant phenotype.

Case Report

At 8 weeks' gestation, a positive antibody screen was found in a group A, D+, gravida 2, 27-year-old, black female. Her first pregnancy was unremarkable and she had no history of transfusion. An antibody investigation revealed anti-Rh17. Her Rh phenotype was D+C–E–c+c+. The initial antibody titer of 32 rose to 64 at 28 weeks and amniotic fluid ΔOD450 values from 30 to 35 weeks' gestation predicted moderate HDN by the Liley method. The pregnancy was otherwise uncomplicated. At 38+ weeks, a viable 3165 g female infant with Apgar scores of 8 and 9 was born by induced vaginal delivery. The infant's RBCs were group A, D+ and the direct antiglobulin test was positive (2+) with anti-IgG. While hemoglobin values remained in an acceptable range, 13 to 13.4 g/dL, total bilirubin rose from 2.6 to 14.2 mg/dL within 48 hours of delivery. Indirect bilirubin peaked at 14.7 mg/dL. After 3 days of triple phototherapy, the total bilirubin was 9.7 mg/dL. The infant was discharged on day 6.

Materials and Methods

Hemagglutination tests

Standard hemagglutination techniques were used throughout. The patient's RBCs were typed with a panel of monoclonal (Mab) anti-e (MS16, MS17, MS19,
HDN due to anti-Rh17

MS21, MS62, MS63, MS69; Bioscot, Ltd.), a monoclonal anti-hr8-like (FOR 2E3), and polyclonal antibodies to high-incidence Rh antigens that included, anti-hr5,-Rh17, -Rh29, and -Rh46. The patient’s serum was tested with a panel of e variants and D– – and Rhnull RBCs by the gel IgG card.

**DNA analysis**

DNA analysis using routine polymerase chain reaction (PCR) techniques that included allele-specific PCR, multiplex PCR, and PCR-restriction fragment length polymorphism (RFLP) was used to characterize the RHD and RHCE genes of the patient.6

**Results**

**Hemagglutination**

The patient’s RBCs typed hr8– with Mab FOR 2E3 and were nonreactive with one example of anti-Rh17. The RBCs were strongly reactive with another example of anti-Rh17. This is not surprising since these antibodies are heterogeneous and the patient is likely to have partial expression of Rh17 (Hr5). The RBCs were strongly reactive with one example of anti-Rh29 and with three examples of anti-Rh46. The RBCs typed hr4+ but were less reactive than the E4+ control RBCs, and they reacted moderately with three of seven Mab anti-e.

The patient’s serum was strongly reactive with a panel of RBCs of normal Rh phenotype and with 6 RBC samples known to carry an e variant phenotype. Two examples each of D– – and Rhnull RBCs were compatible. These results show that the serum contained an antibody with Rh17 specificity. Collectively, our results suggest that the patient’s RBCs carry an e variant phenotype in which epitopes of the Rhce protein are absent and that the patient has produced an antibody (anti-Rh17 or anti-Rh17-like) to the epitopes absent from her RBCs.

**Discussion**

The e blood group antigen is complex, particularly when there is partial expression. In individuals with partial e phenotypes, antibodies with anti-e-like specificity have been described. The specificity of these antibodies often broadens upon repeat transfusion, or following pregnancy,2 so that only RBCs of the D– – or Rhnull phenotypes are compatible. These antibodies are called anti-Hr5 (Rh17) and may have separable components when subjected to complex adsorption and elution procedures. Anti-Rh17 has caused HDN and has been associated with other maternal and fetal complications: spontaneous abortion and maternal hemorrhage have been reported as early as the first pregnancy and in higher order gestations. Infants have been successfully managed with transfusion of washed maternal RBCs and phototherapy, while maternal complications have been corrected with autologous or Rhnull RBC transfusions.3–5 We report moderate HDN successfully managed with phototherapy. Three maternal RBC units were collected during the third trimester, but were not transfused.

The patient’s genotype was RHD, RHCE by DNA analysis. She was homozygous for a 48G>C mutation on the RHCE gene, which in blacks is common and associated with the Ro haplotype. Its association with an e variant phenotype has previously been described only in whites.7 While the serologic studies indicate this patient’s RBCs carry an e variant phenotype, the exact nature of the Rhce protein and which epitopes are absent remains to be defined.

This case of moderate HDN, occurring during a second pregnancy in the presence of anti-Rh17 or anti-Rh17-like, supports the previously reported cases of severe HDN and fetal death associated with anti-Rh17. These risks should be explained to women with this antibody who contemplate multiple pregnancies. As with any antibody to a high-incidence antigen, it is helpful to test samples from the patient’s siblings to find compatible blood.

**Acknowledgments**

We thank Marilyn Moulds, MT(ASCP)SBB; Michele Hill, MT(ASCP); and Karen Stuardi, MT(ASCP)SBB for their contributions to the initial antibody identification. We also thank Dr. Malcolm Rhodes and Dr. Antoine Blancher for generously providing the monoclonal antibodies used in this case study.
References
1. Issitt PD. An invited review: the Rh antigen e, its variants, and some closely related serological observations. Immunology 1991;7:29-36.

Attention SBB and BB Students: You are eligible for a free 1-year subscription to Immunohematology. Ask your education supervisor to submit the name and complete address for each student and the inclusive dates of the training period to Immunohematology, P.O. Box 40325, Philadelphia, PA 19106.

REMEMBER: THE PASSWORD IS “2000” for redcross.org/immunohematology or redcross.org/pubs/immuno

Now, as a subscriber, you can enter the password, 2000, to access complete journal contents for the past 5 years. That means cover to cover! You will receive every article in total, every letter to the editor, every review, every ad, every notice, and every literature review! All of the other services will continue to be available on the Web page, including sending a letter to the editor, subscribing with a credit card on the secure order site, performing a literature search, reviewing instructions for authors, and linking to other important sites. Log on now to see this great service!
MIMA-9, a valuable antibody for screening for rare donors

E. Tossas, R. Øyen, G.R. Halverson, H. Malyska, and M.E. Reid

Since monoclonal antibodies (Mabs) are potentially available in an unlimited volume, they can be used to screen numerous donor blood samples to identify antigen-negative donors. We have used a Mab (MIMA-9) with characteristics that allow for the simultaneous screening of RBCs of any ABO group for high-incidence antigen-negativity in the Kell and Gerbich blood group systems. MIMA-9, a murine IgG2a antibody, previously shown to facilitate the identification of K+k–, Kp(a+b–), K0, McLeod, or Ge:–3 red blood cells (RBCs), was used in MTS gel cards containing anti-mouse IgG as the second antibody to test 1134 K– donors. Among the 1134 donors tested, we found one Kp(a+b–) and one Ge:–2,–3,4 donor. If random donor samples had been used instead of preselecting for K–, we would have expected to identify two K+k– donors. One reagent (MIMA-9) can be used to simultaneously screen for K+k–, Kp(a+b–), K0, McLeod, and Ge:–3 RBCs and thereby conserve rare antisera. Inclusion of anti-mouse IgG in gel cards allowed for rapid screening. MIMA-9 is also a useful reagent to type RBCs with a positive direct antiglobulin test. This antibody is available to donor screening laboratories at no cost for this specific use.


Key Words: monoclonal antibody, anti-k, anti-Kpb, rare donors

In 1975, Kohler and Milstein reported the first example of a murine hybridoma capable of secreting a murine monoclonal antibody (Mab).1 Hybridomas are created by fusing a single stimulated B-cell (secreting an immunoglobulin with the specificity of interest) with a continuously growing myeloma cell. The resultant hybrid cell line secretes an antibody specific for a single epitope. Hybridoma technology has been applied widely in clinical and research laboratories.2–4 We have produced new specificities using novel approaches. Since Mabs are potentially available in unlimited volume, they can be used to screen a large number of blood samples to identify antigen-negative donors. We have used a monoclonal antibody, MIMA-9 (Murine Immunochemistry Monoclonal Antibody), which we produced to screen donor red blood cells (RBCs) of any ABO group for several phenotypes.5 MIMA-9 has an unusual specificity: the Mab reacts strongly with RBCs of common phenotype by the indirect antiglobulin test (IAT) using anti-mouse IgG but does not react with K0 or Kp(a+b–) RBCs, and reacts only weakly with McLeod, K+k–, and some Ge-negative RBCs (because the majority of Ge:–2,–3,4 and Ge:–2,–3,–4 RBCs have depressed Kell antigen expression).6

Materials and Methods

The procedure for the production of this unusual murine IgG2a Mab (MIMA-9) has been described elsewhere. Briefly, cDNAs encoding the common Kell antigens k, Kpb, and Jsb were transfected into MEL-C88 cells by electroporation. The transfected clone with the highest expression of Kell antigens was selected as the immunogen. Standard hybridoma techniques were used to fuse mouse splenocytes with the mouse myeloma cell line X63.Ag8.653 to produce antibody-secreting hybridomas. The Mabs were characterized by serology and flow cytometry.

The pH preference of MIMA-9 was assessed by testing dilutions of the supernatant fluid in phosphate buffered saline (PBS) of different pH values by the IAT in tubes, using sheep anti-mouse IgG (The Binding Site, San Diego, CA). For subsequent testing, MIMA-9 was diluted in PBS/6% bovine serum albumin.

MIMA-9 was tested against 1134 donors of random ABO groups in experimental Micro-Typing System (MTS) gel cards (MTS, Pompano Beach, FL) especially filled by the manufacturer with rabbit anti-mouse IgG. Screening was performed by incubating 25 µL of the supernatant fluid containing Mab MIMA-9 and 50 µL of donor RBCs (0.8%) in the gel cards for 15 minutes at 37°C, and then centrifuging according to the manufacturer’s directions. The donor RBCs tested in our study were preselected to be K–.

Results

Results of testing MIMA-9 at different pHs showed that this Mab is not dramatically sensitive to pH (Table 1). The results obtained using undiluted MIMA-9 supernatant fluid with selected RBCs in PBS at pH 7.3 are shown in Figure 1. At a dilution of 1 in 4 of the supernatant fluid containing MIMA-9 in PBS/6% bovine
serum albumin, comparable results were obtained; this dilution was selected for our screening. Among 1134 donors tested, we found one Kp(a+b–) and one Ge:–2,–3,4 donor. If random donor samples had been used instead of preselecting for K–, we would expect two K+k– donors to have been identified. To confirm the antigen-negative status, RBCs that were nonreactive in our initial screening using MTS gel cards were tested and confirmed with human polyclonal reagents by standard tube IAT.

Conclusion
The testing of 1134 donors with MIMA-9 detected one Kp(a+b–) donor and one Ge:–2,–3,4 donor. In addition, had we used truly “random” donors, we would have expected to find two donors with K+k– RBCs. We previously showed that this one Mab, MIMA-9, can be used to detect K+k–, Kp(a+b–), K0, McLeod, and Ge:–3 RBCs and thereby conserve rare antisera, which are not readily available for mass donor screening. Inclusion of anti-mouse IgG in MTS gel cards allowed for rapid screening of large volumes of random donor RBCs. An additional advantage of this approach is that the Mab can be used for all ABO groups.

MIMA-9 is unusual in that, while it is nonreactive with Kp(a+b–) RBCs, it is only weakly reactive with K+k– RBCs. It was also surprising that Ge:–2,–3,4 and Ge:–2,–3,–4 RBCs were weakly reactive; however, it has been reported that most such RBCs have a weak expression of Kell antigens. Thus, we conclude that the epitope recognized by MIMA-9 is highly conformation-dependent, is located on the Kell glycoprotein, and requires the presence of glycophorin C. We have taken advantage of this characteristic to perform mass screening with the Mab to identify several different high-incidence antigen-negative donors. Once we find a RBC sample that is nonreactive with MIMA-9, appropriate testing is performed to identify the actual phenotype of the donor. We will make MIMA-9 available to anyone who would like to include it in their screening program.

Acknowledgments
We thank Christine Lomas-Francis for critically reviewing the paper and Robert Ratner for preparing the manuscript and figure. This study was supported in part by a National Institutes of Health Specialized Center of Research (SCOR) grant (HL54459) in Transfusion Biology and Medicine.

References
5. Tossas E, Øyen R, Reid ME, Malyska H. MIMA-9, a valuable antibody for screening for rare donors (abstract). Transfusion 2000;40(Suppl):126S.

Edith Tossas, Immunohematology Laboratory, New York Blood Center, 310 East 67th Street, New York; Ragnbild Øyen, Immunohematology Laboratory, New York Blood Center, 310 East 67th Street, New York; Gregory R. Halverson, MT(ASCP) SBB, DLIM, Immunohemistry Laboratory, New York Blood Center, 310 East 67th Street, New York; Harry Malyska, BS, MT(ASCP) SBB, Vice President and Regulatory Head, Micro Typing Systems, Inc., 1295 S.W. 29th Avenue, Pompano Beach, Florida 33069; and Marion E. Reid, PhD, (corresponding author), Immunohemistry Laboratory, New York Blood Center, 310 East 67th Street, New York, New York 10021. marion_reid@nybc.org

Manuscripts: The editorial staff of Immunohematology welcomes manuscripts pertaining to blood group serology and education for consideration for publication. We are especially interested in case reports, papers on platelet and white cell serology, scientific articles covering original investigations, and papers on the use of computers in the blood bank. Deadlines for receipt of manuscripts for the March, June, September, and December issues are the first weeks in November, February, May, and August, respectively. Instructions for scientific articles and case reports can be obtained by phoning or faxing a request to Mary H. McGinniss, Managing Editor, Immunohematology, at (301) 299-7443, or see “Instructions for Authors” in every issue of Immunohematology or on the Web. Include fax and phone numbers and e-mail address with your manuscript.

IMPORTANT NOTICE ABOUT MANUSCRIPTS FOR IMMUNOHEMATOLOGY
Submit all manuscripts (original and 2 copies) to Mary H. McGinniss, Managing Editor, 10262 Arizona Circle, Bethesda, MD 20817. Please include the manuscript on a 3 1/2 inch disk, in Microsoft Word 97/6.0 or WordPerfect 6.0/5.1, and e-mail a copy to mmanigly@usa.redcross.org
Confirmation that the JAHK antigen is associated with the rG haplotype

J. Kosanke, J.R. Storry, and M.E. Reid

Anti-JAHK, an antibody directed toward a low-incidence antigen in the Rh system, was detected during routine antibody identification in a male donor who had no history of transfusion. Examples of anti-JAHK have been found in sera containing multiple antibodies to low-incidence antigens. The first report of anti-JAHK was in 1995 and described the association of the JAHK antigen with the rG haplotype. Our results confirm this association.

Key Words: low-incidence antigen, anti-JAHK, rG haplotype, Rh blood group antigen

Green et al. first reported the JAHK antigen in 1995.1 It was recognized as a new antigen when several sera containing multiple antibodies to other low-incidence antigens were reactive with red blood cells (RBCs) of two siblings. The RBCs from both siblings had a weak expression of the C antigen similar to that produced by the rG haplotype [d(C)(e)G]. Family members who did not inherit the rG haplotype were nonreactive with the new antibody. Another example of RBCs defined as rGr was also reactive, but RBCs that were rG were nonreactive. Two additional families were found with JAHK+ RBCs. In one family, the RBCs were studied because of weak expression of both C and e antigens in a person whose RBCs typed as D+C+E+c+e+. In the other family, the RBCs were studied because they reacted with a serum with multiple antibodies to low-incidence antigens. From observations in these three unrelated families, the JAHK antigen appeared to be produced by the rG haplotype.

We report another example of anti-JAHK and confirmation of the association of this antigen with the rG haplotype.

Case Report

A sample from a blood donor was referred to American Red Cross Blood Services, Central Ohio Region, for antibody identification. The sample was then sent to the New York Blood Center for further study. A panel of reagent RBCs was tested by a saline-indirect antiglobulin test (IAT). The donor's plasma, which contained anti-E and -Cw, reacted with one E-, Cw- RBC sample (donor T12) on the panel. These RBCs had the rGr phenotype.

Materials and Methods

Standard serologic techniques were used throughout. Reagent RBC panels were obtained from Immucor, Inc. (Norcross, GA); anti-IgG was from Gamma Biologicals, Inc. (Houston, TX). An aliquot of the incompatible panel RBCs (donor T12) was kindly provided by Immucor, Inc. To isolate the antibody and permit testing of additional RBCs regardless of ABO group, the donor's plasma was adsorbed onto an equal volume of rGr RBCs for 1 hour at 37°C. The antibody was eluted from these cells using a commercial kit (EluKit II, Gamma Biologicals, Inc.). This eluate was also tested with four rG RBC samples. The plasma was tested with RBCs known to express the following low incidence antigens: An, Co, Crawford, Dantu, Di, Go, Kp, Ls, Lu14, M, Mur, Hil, Js, Mt, Sc2, Rd, Tc, V, and Wr.
admission. These antibodies, along with anti-Wr\(^a\), -M\(^b\), and -JAHK identified in the current sample, appear to be naturally occurring. Thus, anti-JAHK has only been found in sera containing antibodies to multiple low-incidence antigens.

An eluate containing anti-JAHK reacted with four previously untested r\(^O\) RBC samples, providing further evidence that JAHK is an antigen carried by the r\(^O\) haplotype. Nonreactivity of the r\(^O\) RBCs with the eluate confirmed the specificity.

**Addendum**

While this paper was in review, a current paper by Green et al.\(^2\) reported that the ISBT has assigned Rh53 to the JAHK antigen.

---

**References**


Joanne Kosanke, MT(ASCP)SBB, American Red Cross Blood Services, Central Ohio Region, 995 East Broad Street, Columbus, OH 43205-1339; Jill Storry, PhD, FIBMS, New York Blood Center, New York, NY; Marion Reid, PhD, FIBMS, New York Blood Center, New York, NY.

---

**Notice to Readers:** All articles published, including communications and book reviews, reflect the opinions of the authors and do not necessarily reflect the official policy of the American Red Cross.

---

**Attention: State Blood Bank Meeting Organizers**—If you are planning a state meeting and would like copies of *Immunohematology* for distribution, please contact Mary McGinniss, Managing Editor, 4 months in advance, by phone or fax at (301) 299–7443.

---

**Notice to Readers:** *Immunohematology, Journal of Blood Group Serology and Education*, is printed on acid-free paper.
B O O K    R E V I E W


Practical Guide to Transfusion Medicine is a useful, informative, and remarkably up-to-date textbook that is highly recommended to readers of Immunohematology, Journal of Blood Group Serology and Education. Drs. Marian Petrides and Gary Stack provide an overview of clinical transfusion practice, basic blood group immunohematology, and fundamentals of blood bank management in a readable and concise format. This paperback guide is now required reading for our medical center's Clinical Pathology residents, because it answers the most frequently asked questions in a hospital transfusion service with reliable and practical information.

The special interests of readers of Immunohematology are well-served by Dr. Stack’s chapter on Carbohydrate-Based Blood Groups and Collections and a companion chapter on Peptide Blood Groups. Dr. Stack is a specialist in transfusion medicine who holds BS and PhD degrees in biochemistry, and who also completed a fellowship in molecular biology. He is expertly qualified and he presents blood group immunology with the precision, clarity, and detail that should satisfy the needs of laboratory-based immunohematologists. Dr. Petrides authored the chapters that address hemolytic disease of the newborn, neonatal alloimmune thrombocytopenia, platelet refractoriness, and calculations to determine the likelihood of finding compatible blood. The latter chapter contains a handy table of blood group antigen frequencies by race. Dr. Petrides adds useful guidance for estimating the frequencies of certain phenotypes which, because of their different distributions among populations according to race, do not segregate as truly independent variables.

A book reviewer should note deficiencies and, as expected, they can be found in any first edition, especially one that is crammed with technical information. The following sentence should be revised in the next edition: “...administration of RhIG or Rh IVIG is also recommended at 26–28 weeks of gestation for Rh-negative mothers when the father is Rh-negative or his Rh status is unknown” (pg. 280). Clearly, the authors intended “father is Rh-positive.” There are (only) two photographic illustrations. The first is a photograph of a “plasma expresser.” The priority for this photograph of laboratory equipment is unclear. The second is a reproduction of Immucor’s widely-circulated illustration that compares the standard grading system for test tube agglutination reactions with scoring for Immucor’s solid-phase red cell adherence assay (SPRCA). The SPRCA scores are barely discernible. A few pages later, the authors discuss SPRCA methodology using a line drawing as a model. However, the drawing of a “positive” reaction, which it describes as a uniform blush of indicator RBCs, is represented, erroneously, by a clear unshaded circle (pg. 39). The book has an errata sheet that identifies corrections needed for figures 3-7 and 5-8. Lastly, the Appendix, which is otherwise comprehensive and pertinent, provides the names and addresses for 13 journals intended to be “of interest to blood bank and transfusion medicine professionals.” As I prepare this review, I feel obligated to note the absence of Immunohematology, a highly pertinent journal, from the list.

In balance, these few “first edition slips” are only minor distractions when weighted against the many contributions that Practical Guide to Transfusion Medicine will make educating trainees, providing a concise review for veteran blood bankers, and providing other healthcare professionals an informative, reliable, and affordable guide to transfusion practices.

S. Gerald Sandler, MD, FACP, FCAP
Professor of Medicine and Pathology
Director, Transfusion Medicine
Georgetown University Medical Center
Washington, DC 20007
SPECIAL ANNOUNCEMENT

27th Congress of the International Society of Blood Transfusion
Vancouver Convention and Exhibition Centre * August 24 - 29, 2002

PROGRAM HIGHLIGHTS
Stem Cells
Blood Conservation / Transfusion Alternatives
Minimizing Accidents and Errors
Apheresis
Computerization in Transfusion Medicine
Bacterial Contamination
Adverse Reactions to Blood Products
Transfusion Medicine in the Developing World
Ethics of Transfusion Medicine
ISBT 128 Labelling
Transfusion Triggers
Web-based Educational Resources
Recruitment of New Blood Donors
Clinical Trial Design and Evaluation
Apoptosis and Cellular Product Storag
Evidence Based Medicine / Health Services
...and many others

ORGANIZING COMMITTEE
Dr. Noel Buskard
Congress President
Dr. Francis Decary
Congress Vice-President
Edna S. Bihm, ART
Finance Chair
Kathy Chambers, ART
Co-Chair, Organizing Committee
Astrid Maudrie, MLT, ART
Co-Chair, Organizing Committee
Dr. Dana Devine
Scientific Program Chair
Scientific Steering Committee
Dr. Gail Rock
Member at Large

Visit our website regularly for program, registration and abstract submission details/updates:
www.isbt2002.com
Masters (MSc) in Transfusion and Transplantation Sciences
At
The University of Bristol, England

Applications are invited from medical or science graduates for the Master of Science (MSc) degree in Transfusion and Transplantation Sciences at the University of Bristol. The course starts in October 2002 and lasts for one year. A part-time option lasting three years is also available. There may also be opportunities to continue studies for a PhD or an MD following the MSc. The syllabus is organized jointly by The Bristol Institute for Transfusion Sciences and the University of Bristol, Department of Transplantation Sciences. It includes:

• Scientific principles underlying transfusion and transplantation
• Clinical applications of these principles
• Practical techniques in transfusion and transplantation
• Principles of study design and biostatistics
• An original research project

Application can also be made for a Diploma in Transfusion and Transplantation Science or a Certificate in Transfusion and Transplantation Science.

The course is accredited by the Institute of Biomedical Sciences.

Further information can be obtained from the Web site:
http://www.bloodnet.nhs.uk/ibgrl/MscHome.htm

For further details and application forms please contact:

Professor Ben Bradley
University of Bristol, Department of Transplantation Sciences
Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, England
Fax +44 1179 595 342, telephone +44 1779 595 455, e-mail: ben.bradley@bristol.ac.uk
Monoclonal antibodies available. The New York Blood Center has developed murine monoclonal antibodies that are useful for donor screening and for typing red cells with a positive direct antiglobulin test. Anti-Rh17 is a direct agglutinating monoclonal antibody. Anti-Fy\(a\), anti-K, anti-J\(s^b\), and anti-Kp\(a\) are indirect agglutinating antibodies that require anti-mouse IgG for detection. These antibodies are available in limited quantities at no charge to anyone who requests them. Contact: Marion Reid, New York Blood Center, 310 E. 67th Street, New York, NY 10021; e-mail: mreid@nybc.org

CLASSIFIED AD

SBB Program: The Department of Transfusion Medicine, National Institutes of Health (NIH), is accepting applications for its 1-year Specialist in Blood Bank Technology Program. Students are federal employees: GS-644/9 medical technologists who work 32 hours per week. This program introduces students to all areas of transfusion medicine, including reference serology, cell processing, and HLA and infectious disease testing. Students also design and conduct a research project. NIH is an Equal Opportunity Organization. Application deadline is June 30, 2002, for the January 2003 class. Contact: Karen M. Byrne, NIH/CC/DTM, Bldg. 10, Rm. 1C711, 10 Center Drive MSC 1184, Bethesda, MD 20892-1184. Phone: (301) 496-8355, e-mail: kcipolone@dtm.cc.nih.gov
Reference and Consultation Services

Red cell antibody identification and problem resolution
HLA-A, B, C, and DR typing
HLA-disease association typing
Paternity testing/DNA

For information regarding our services, contact Zahra Mehdizadehkashi at (503) 280–0210, or write to:

Pacific Northwest Regional Blood Services
ATTENTION: Tissue Typing Laboratory
American Red Cross
3131 North Vancouver
Portland, OR 97227

CLIA licensed, ASHI accredited

National Platelet Serology Reference Laboratory

Diagnostic testing for:
• Neonatal alloimmune thrombocytopenia (NAIT)
• Posttransfusion purpura (PTP)
• Refractoriness to platelet transfusion
• Heparin-induced thrombocytopenia (HIT)
• Alloimmune idiopathic thrombocytopenia purpura (AITP)
• Medical consultation available

Test methods:
• GTI systems tests
  — Detection of glycoprotein-specific platelet antibodies
  — Detection of heparin-induced antibodies (PF4 ELISA)
• Platelet suspension immunofluorescence test (PSIFT)
• Solid phase red cell adherence (SPRCA) assay
• Monoclonal antibody immobilization of platelet antigens (MAIPA)

For information, e-mail: immuno@usa.redcross.org
or call:
Maryann Keashen-Schnell
(215) 451–4041 office
(215) 451–4205 laboratory
Sandra Nance
(215) 451–4362
Scott Murphy, MD
(215) 451–4877

American Red Cross Blood Services
Musser Blood Center
700 Spring Garden Street
Philadelphia, PA 19123–3594

CLIA licensed

IgA/Anti-IgA Testing

IgA and anti-IgA testing is available to do the following:
• Monitor known IgA-deficient patients
• Investigate anaphylactic reactions
• Confirm IgA-deficient donors

Our ELISA assay for IgA detects antigen to 0.05 mg/dL.

For information on charges and sample requirements, call (215) 451–4351, e-mail: achurch@usa.redcross.org,
or write to:

American Red Cross Blood Services
Musser Blood Center
700 Spring Garden Street
Philadelphia, PA 19123–3594
Attn: Ann Church

CLIA licensed
LITERATURE REVIEW


Blood group antigens
10. Storry JR, Reid ME, MacLennan S, Lubenko A, Nortman P. The low-incidence MNS antigens M(V), s(D), and Mit arise from single amino-acid substitutions on GPB. Transfusion 2001;41:53-5.

Blood group antibodies
Blood group genetics


Monoclonal antibodies


Red cell serology/methods


White cell/platelet serology

Hemolytic anemias

Hemolytic disease of the newborn


**Transfusion/transplantation**


**Disease associations**


Miscellaneous
Instructions for Authors

SCIENTIFIC ARTICLES, REVIEWS, AND CASE REPORTS

Before submitting a manuscript, consult current issues of Immunohematology for style. Type the manuscript on white bond paper (8.5” × 11”) and double-space throughout. Number the pages consecutively in the upper right-hand corner, beginning with the title page. Each component of the manuscript must start on a new page in the following order:
1. Title page
2. Abstract
3. Text
4. Acknowledgments
5. References
6. Author information
7. Tables—see 6 under Preparation
8. Figures—see 7 under Preparation

Preparation

1. Title page
   A. Full title of manuscript with only first letter of first word capitalized
   B. Initials and last name of each author (no degrees; all CAPS), e.g., M.T. JONES
   C. Running title of ≤40 characters, including spaces
   D. 3 to 10 key words

2. Abstract
   A. 1 paragraph, no longer than 200 words
   B. Purpose, methods, findings, and conclusions of study
   C. Abstracts not required for reviews

3. Text (serial pages)
   Most manuscripts can usually, but not necessarily, be divided into sections (as described below). Results of surveys and review papers are examples that may need individualized sections.
   A. Introduction
      Purpose and rationale for study, including pertinent background references.
   B. Case Report (if study calls for one)
      Clinical and/or hematologic data and background serology.
   C. Materials and Methods
      Selection and number of subjects, samples, items, etc. studied and description of appropriate controls, procedures, methods, equipment, reagents, etc. Equipment and reagents should be identified in parentheses by model or lot and manufacturer’s name, city, and state. Do not use patients’ names or hospital numbers.
   D. Results
      Presentation of concise and sequential results, referring to pertinent tables and/or figures, if applicable.
   E. Discussion
      Implications and limitations of the study, links to other studies; if appropriate, link conclusions to purpose of study as stated in introduction.

4. Acknowledgments
   Acknowledge those who have made substantial contributions to the study, including secretarial assistance.

5. References
   A. In text, use superscript, arabic numbers.
   B. Number references consecutively in the order they occur in the text.
   C. Use inclusive pages of cited references, e.g., 1431–7.
   D. Refer to current issues of Immunohematology for style.

6. Tables
   A. Number consecutively, head each with a brief title, capitalize first letter of first word (e.g., Table 1. Results of ...), and use no punctuation at the end.
   B. Use short headings for each column, and capitalize first letter of first word.
   C. Place explanations in footnotes (sequence: *, †, ‡, §, ¶, **, ††).

7. Figures
   A. Figures can be submitted either drawn or photographed (5” × 7” glossy).
   B. Place caption for a figure on a separate page (e.g., Fig. 1. Results of ...), ending with a period. If figure is submitted as a glossy, put title of paper and figure number on back of each glossy submitted.
   C. When plotting points on a figure, use the following symbols when possible: ○ ● ▲ ■.

8. Author information
   A. List first name, middle initial, last name, highest academic degree, position held, institution and department, and complete address (including zip code) for all authors. List country when applicable.

SCIENTIFIC ARTICLES AND CASE REPORTS SUBMITTED AS LETTERS TO THE EDITOR

Preparation

1. Heading—To the Editor:
2. Under heading—title with first letter capitalized
3. Text—write in letter format (paragraphs)
4. Author(s)—type flush right; for first author: name, degree, institution, address (including city, state, and zip code); for other authors: name, degree, institution, city, and state.
5. References—limited to ten.
6. One table and/or figure allowed.

Send all submissions (original and two copies) to:
Mary H. McGinniss, Managing Editor, Immunohematology, 10262 Arizona Circle, Bethesda, MD 20817.
Include your manuscript on a 3 1/2” disk, in Microsoft Word 97/6.0 or Word Perfect 6.0/5.1 and e-mail your manuscript to mmanigly@usa.redcross.org